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A B S T R A C T
The novel coronavirus (2019-nCoV) is an emerging pathogen that was first described in late December 2019 and
causes a severe respiratory infection in humans. Since the outbreak of COVID-19, international attention has
raised to develop treatment and control options such as types of immunotherapies.
The immunotherapy is an effective method for fighting against similar viral infections such as SARS-CoV, and
MERS-CoV. These methods include several types of vaccines, monoclonal antibody candidates, and etc.
This systematic review article was designed to evaluate the existing evidence and experience related to im-
munotherapy for 2019-nCoV. Web of Science (ISI), PubMed, and Scopus databases were used to search for
suitable keywords such as 2019-nCoV, novel coronavirus, Immunotherapy, interleukin, vaccine and the related
words for relevant publications up to 24.3.2020. The present systematic review was performed based on PRISMA
protocol. Data extraction and quality valuation of articles were performed by two reviewers. 51 articles were the
results of the search and based on the inclusions and exclusions criteria, 7 articles were included in the final
review.
As a conclusion of these studies demonstrated that although no serious research has been done on this subject
at the time of writing this article, similar studies on the related viruses showed notable results. So im-
munotherapy for this virus can also be a suitable option.
1. Background
2019-nCoV a large enveloped virus with a positive sense, single-
stranded RNA genome, is the third known coronavirus after SARS-CoV
and MERS-CoV that was first identified in late December 2019 and
causes severe respiratory illness and pneumonia-like infection in hu-
mans [1,2]. WHO has declared the pandemic outbreak of novel cor-
onavirus (2019-nCoV) as a global health emergency. Immunotherapy is
an efficient therapeutic option intervention against viral infections.
Most immunotherapy attempts have been successful to fight against
similar COVID-19 viruses such as SARS-CoV and MERS-CoV. The main
methods in this regard include several vaccines and monoclonal anti-
body candidates. Furthermore, according to existing evidence in
fighting against viral infections such as Ebola, influenza, SARS, and
MERS plasma exchange can likely reduce the viral load and disease
mortality [3,4].
In both SARS-CoV and SARS-CoV-2 viruses entry into the host cells
is mediated by interaction of the receptor-binding domain (RBD) in S
protein on virus outer-membrane and angiotensin-converting enzyme 2
(ACE2) on cell. So, these proteins can be the major potential targets for
immunotherapy [1,5]. The increasing knowledge of MERS-CoV and
SARS-CoV immunotherapies in recent years might increase the oppor-
tunities to design effective same therapeutics for novel coronavirus [3].
Despite the relatively high identity of RBD in 2019-nCoV and SARS-
Co, it is necessary to develop novel monoclonal antibodies that could
bind specifically to 2019-nCoV RBD since some of the most potent
SARS-CoV-specific neutralizing antibodies (e.g. m396, CR3014) that
target the ACE2 binding site of SARS-CoV failed to bind 2019-nCoV
spike protein, implying that the difference in the RBD of SARS-CoV and
2019-nCoV [5].
Our purpose in this article is to review immunotherapeutic attempts
against 2019-nCoV and to list current investigational im-
munotherapeutic strategies for 2019-nCoV.
2. Methods
The present systematic review article was performed based on
PRISMA protocol [6] (Table S1).
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2.1. Search strategy
Web of Science (ISI), PubMed, and Scopus databases were used to
search for the proper keywords such as: 2019-nCoV, novel coronavirus,
Immunotherapy, interleukin, vaccine and the related words for pub-
lications published until 24.3.2020. The search strategies are available
in the supplementary data (Table S2). Titles and abstracts were sepa-
rately reviewed by two authors (A.AJ and S.GH) to detect potentially
related articles. The full texts of articles that appeared confusing were
evaluated to determine their appropriateness for inclusion.
2.2. Included studies
The studies reviewed in this article were about the categories of
immunotherapy (monoclonal antibody, interleukins, vaccines, etc.) for
all three coronaviruses, but they must have been mentioned use of
immunotherapy for treatment or control of 2019-nCoV.
2.3. Excluded studies
The articles with only abstract were excluded from this review.
Some articles were also excluded because they were only about SARS
and MERS without any discussion or outlook on the 2019-nCoV.
2.4. Data extraction
Data from articles were extracted independently by two reviewers
to fill in table items.
2.5. Quality assessment
Quality of each publication was evaluated by two independent re-
viewers (A.AJ and S.GH). This review addressed 7 domains: Type of
immunotherapy, Dedicated or for other viruses, Treatment/
Interventions, Accompanied by another treatment, Number of patients
treated (percent improved), Outcomes, results and clinical outcome.
2.6. Statistical analysis:
It was not possible to conduct a meta-analysis because there was not
enough proper research studies on this subject.
3. Results
3.1. Study selection
We retrieved a total of 51 potentially eligible articles from initial
database searches, 14 articles were excluded because of being dupli-
cate. 30 articles were also excluded because they were review articles
or addressed other virusess or their full text were not accessible.
Therefore, a total of 7 articles were included in final analysis (Fig. 1).
3.2. Study characteristics (Eligibility criteria)
According to inclusion criteria stated in the protocol, articles were
included in English language without any date restriction. We updated
the search process in PubMed, WOS and Scopus up to 24.3.2020.
Endnote library (version X6, Thomson Reuters) was used to import
Citations from all databases and duplicate citations were removed. The
title and abstract of the remainder of the search results were reviewed
Fig. 1. Flowchart of the articles selection.
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by both authors to exclude irrelevant studies. Full texts of the re-
mainder of the citations were collected for further screening and data
extraction. Included studies were original articles published until
24.3.2020 and most publications were related to 2020 with the aim to
manage and control corona virus pandemic by several types of im-
munotherapy.
4. Results
According to the extracted data in Table 1, all immunotherapy at-
tempts for 2019-nCoV until now include polyclonal antibody by Plasma
therapy, Polypeptide hormone for maturation of T cells, im-
munoglubolins, ACE2 immunoadhesin and monoclonal antibody
against the interleukin-6. other interventions such as viral-vectors, na-
noparticles, inactivated whole virus and DNA as vaccines and mono-
clonal antibody have been used for SARS-CoV that holds the promise
for using in 2019-nCoV.
Plasma therapy and immunoglobulin intervention on 2019-nCoV
infected patients could improve clinical outcome. The vaccines and
ACE2 immunoadhesin have not been tested yet. As the preferred im-
munotherapy method, monoclonal antibody has performed only for
SARS; however, this method has not yet been tested. Most articles in
this field are review articles recommending immunotherapy for 2019-
nCoV with reasons and evidence of previous studies on two other cor-
onaviruses SARS-CoV and MERS-CoV.
There is only one clinical trial study in the field that mentions some
of these methods on 2019-nCoV [7].
5. Discussion
As both SARS-CoV and SARS-CoV-2 (2019-nCoV) have the same
receptor for virus entry, potential biotherapeutics to prevent SARS
entry could be extrapolated to use for SARS-CoV-2. Among im-
munotherapy approaches to block the virus attachment or entry,
monoclonal antibodies are preferred due to their specificity, purity, low
risk of blood-borne pathogen contamination and safety compared to
serum therapy and intravenous immunoglobulins preparations [3].
The promising results in targeting spike protein in SARS-CoV and
MERS-CoV by monoclonal antibodies encourages researchers to use
them in fighting against 2019-nCoV. Monoclonal antibody cocktail or
the combination of different monoclonal antibodies that recognizes
different epitopes on the viral surface may increase the effectiveness of
virus neutralizing [3].
Other targets in immunotherapy for COVID-19 that seem to be
Promising are cytokines. Among cytokines, specificity of IL-6 in COVID-
19 comes from that Elevated IL-6 is correlated with inflammatory cy-
tokine storm severity. Therefore targeting IL-6 and its receptor (IL6R)
by Siltuximab and tocilizumab monoclonal antibodies (mAb) could
mitigate cytokine storm-related symptoms in severe COVID-19 patients
[13].
Despite major progress in the development of monoclonal antibody-
based passive immunotherapy for coronavirus infection, there is no
marketed monoclonal antibody. What limits the use of antibodies is that
large-scale production of monoclonal antibodies for clinical application
is laborious, expensive and time-consuming. So designing and devel-
oping advanced protein production platforms and expression systems is
urgent to provide efficient monoclonal antibodies at the affordable cost
in a short time [3].
Although no research has been tested, and there is no approved
vaccines or anti-viral therapeutic agents to treat COVID-19 until now,
the vaccines can be successful due to the specific structure of the virus.
Furthermore, existing evidence on immunotherapy for SARS-CoV and
MERS-CoV holds the promise for using in 2019-nCoV.
6. Conclusion
As is evident from this systematic review, immunotherapy is an
efficient therapeutic option intervention against COVID-19 and the
main methods in this regard such as using immunoglobulins and plasma
therapy have improved clinical outcomes in COVID-19 infected pa-
tients.
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